Intellia Stock Falls Amid Safety Concerns Over Gene-Editing Drugs
Intellia Therapeutics' stock dropped 19% after a safety update revealed a case of elevated liver enzymes in its ongoing Phase 3 trial for gene therapy, though the event is resolving without severe intervention. Despite the incident, analysts remain cautiously optimistic, citing the rarity of the event and ongoing positive trial progress, with some viewing the market reaction as an overreaction.